Pharmaceutical group Novartis raised
its net profit by 7 per cent to 2.42 billion dollars in the first
quarter, as business grew in emerging markets and demand for its new
products improved, the Swiss company said Wednesday in Basel.
Europe's largest medicine group made revenues worth 14.02 billion dollars, 2 per cent higher than in the first three quarters of 2012.
Sales improved especially in Russia and China.
Novartis said several recently developed products sold well at the start of the year, including medicines to treat multiple sclerosis, organ transplants and leukemia.
Operating profit rose 6 per cent to 2.9 billion dollars, as Novartis further cut costs by narrowing the number of production sites.
The company announced it would cut 300 jobs at its US plant in Lincoln, Nebraska, where authorities had detected quality problems.
Novartis faces new problems in the United States, as New York prosecutors announced a lawsuit against the company on Tuesday, alleging a multi-million-dollar kickback scheme for pharmacies that defrauded public health care services.
Despite the improved earnings, the company expects its operating profit to fall by a mid-single digit number this year, from last year's 11.51 billion dollars, owing to competition from generic medicines, as well as investment in a large number of new products.
Novartis was among the few losers on the Swiss Exchange in Zurich on Wednesday, with its stocks falling by 0.87 per cent to 68.65 Swiss francs (72.55 dollars) during morning trading.
Most Popular Stories
- Homeowners More Satisfied With Mortgage Servicers
- Discounts Help U.S. Auto Sales Sizzle in July
- Russia, Ukraine Now Face Off Over Football Clubs
- Colorado Issuing Immigrant Driver's Licenses
- Recruiting and Keeping the Perfect Employee
- MassMutual Teams Up With ALPFA
- Chrysler U.S. Sales in July Hit 9-Year High
- Fiat Looks Abroad After Chrysler Merger Vote
- Dow Wipes Out Gains for the Year: What Happens Now?
- House Shelves Immigration Bill, Goes on Vacation